Defendant
2 cases as defendant.
Company overview. Handa Pharmaceuticals, LLC is a Delaware LLC founded in November 2005 by Dr. Fangyu Liu in the San Francisco Bay Area, with offices in San Jose, California (per court filings and Crunchbase). It is a U.S. operating subsidiary of Taiwan-based Handa Pharmaceuticals, Inc. (TPEX: 6620), a specialty-pharma company listed on the Taipei Exchange (regular board listing December 2025). Public data from PitchBook puts the parent group at roughly 48 employees, ~US$57M trailing-twelve-month revenue, and a ~US$396M market cap as of mid-2026; revenue for the LLC itself is not publicly disclosed.
Products / operations. Handa develops 505(b)(2) new drugs and high-barrier generic prescription products for the U.S. market. Within the group, the LLC runs the generics business, while Handa Pharma, Inc. handles business development, IP, and regulatory affairs and Handa Neuroscience, LLC handles CNS brand products. Known products include TASCENSO ODT (fingolimod lauryl sulfate orally disintegrating tablets, 0.5 mg, for multiple sclerosis, marketed in the U.S. by Cycle Pharmaceuticals), generic Quetiapine XR, Dexlansoprazole DR capsules, varenicline tablets, and the ONCORE oncology drug-delivery platform, plus a pipeline (HND-033/039/027, HND-004, HND-026).
Patent-litigation posture. Handa is an operating company, not an NPE. Its one tracked case is as defendant (0 plaintiff cases): Novartis Pharmaceuticals Corp. v. Handa Neuroscience, LLC et al. in the District of Delaware, a Hatch-Waxman/ANDA suit — consistent with a branded/generic drugmaker defending a regulatory submission, not a patent-assertion campaign.
Notable case. Filed May 4, 2021, Novartis asserted GILENYA® patents (U.S. 9,187,405 and 10,543,179) against NDA No. 214962 (TASCENSO ODT); a parallel "safety suit" ran in the Northern District of California. The parties settled in October 2022 via a consent judgment, with Handa taking a license and agreeing to royalty payments on net sales under specified conditions, clearing the way for final FDA approval. Handa characterized the suit as routine patent-challenge litigation in 505(b)(2) drug development.
Protective safety suit filed in the Northern District of California two days after the Delaware Handa suit, asserting the same two patents. Dismissed after the October 2022 Handa settlement.
Suit against Handa entities asserting the '405 patent and also US 10,543,179. Handa sought summary judgment on the '405 patent after the Federal Circuit's June 2022 invalidation; final disposition not verified.